Market Access Views & Analysis

Views & Analysis

Oslo Medicines Initiative asks how to balance innovation inc...

Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution that works for everyone.

Digital

Nine for 2022: innovation and opportunities in healthcare

In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which have, as they did in 2021, a pervasive effect on

R&D

Nine for 2022: International issues that are compelling, new...

The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials.

Patients

Hand flips a block changing 2021 to 2022. New year beginning. Holidays and Christmas. Trends and changes in the World. Summing work done. Build plans. New normal. Keep up with everything planned.

2021 in review: Building the framework of a patient-centric ...

Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action.

Oncology

Regulation optimisation could save thousands of life years

Embracing a “once-in-a-generation opportunity” to improve access to oncology treatments could save thousands of years of life across the European Union.

Market Access

Post-Brexit medicines regulation must have international sco...

Post-pandemic, post-Brexit Britain must create a regulatory framework that both defines and aligns with international standards, or risk being left behind.